MARKET

RARE

RARE

Ultragenyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.08
-0.70
-1.90%
After Hours: 36.08 0 0.00% 16:09 11/15 EST
OPEN
37.18
PREV CLOSE
36.78
HIGH
37.38
LOW
36.02
VOLUME
506.28K
TURNOVER
--
52 WEEK HIGH
74.50
52 WEEK LOW
36.13
MARKET CAP
2.08B
P/E (TTM)
-4.9897
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RARE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

RARE News

  • Ultragenyx Pharmaceutical (RARE) Investor Presentation - Slideshow
  • Seeking Alpha - Article.2d ago
  • Edited Transcript of RARE earnings conference call or presentation 5-Nov-19 10:00pm GMT
  • Thomson Reuters StreetEvents.6d ago
  • Ultragenyx Pharmaceutical Inc. 2019 Q3 - Results - Earnings Call Presentation
  • Seeking Alpha - Article.11/08 15:59
  • After son’s rare disease diagnosis, father finds hope through film festival
  • American City Business Journals.11/08 15:02

More

Industry

Biotechnology & Medical Research
+1.49%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Name
Price
%Change

About RARE

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
More

Webull offers Ultragenyx Pharmaceutical Inc (RARE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.